Intrathecal drug delivery for chronic pain management continues to evolve. The INS’s Polyanalgesic Consensus Conference (PACC) recommendations and webinars meet a growing need for updated guidance on emerging evidence, and changes in best practices for patient care, and to fill current gaps in clinical practice. The goal of this educational activity is to improve safety and efficacy of the global use of intrathecal therapy (IT). The faculty of this webinar series may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty members have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
INS Webinar Series on The Polyanalgesic Consensus Conference (PACC): Algorithmic Approach to Intrathecal Drug Delivery for Different Pain Syndromes (Enduring)
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Details
Learning Objectives
Upon completion of this activity, the participant should be able to: - Explain best practices for patient selection for intrathecal drug delivery.
- Identify the differences and similarities between treating cancer pain and non-cancer pain using intrathecal drug delivery.
- Describe the contemporary issues and techniques for trailing intrathecal drug delivery systems.
Accreditation
Jointly Provided by Evolve Medical Education, LLC and Mantra Meetings. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC; Mantra Meetings; and the International Neuromodulation Society (INS). Evolve Medical Education; LLC is accredited by the ACCME to provide continuing medical education for physicians. Evolve Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.The following faculty/staff members have the following financial relationships with commercial interests:
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.- Magdalena Anitescu, MD, PhD, FASA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Medtronic, Boston Scientific.
- Brian M. Bruel, MD, MBA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Medtronic, TerSera Therapeutics, Abbott, Boston Scientific; Speaker’s Bureau: TerSera Therapeutics, Medtronic, Boston Scientific.
- Timothy R. Deer, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Abbott, Vertos Medical, Flowonix, Axonics, SpineThera, Saluda, Nalu, CornerLoc, SPR Therapeutics, Stimgenics, SI-BONE, Nevro, Medtronic, Boston Scientific, PainTEQ; Grant/Research Support: Abbott, Vertos, Saluda Medical, Mainstay, SPR Therapeutics, Boston Scientific; Shareholder: Options Only: Vertos Medical, Axonics, SpineThera, Saluda, Nalu, CornerLoc, SPR Therapeutics, PainTEQ.
- Denis Dupoiron, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Medtronic, Riemser.
- Robert M. Levy, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Shareholder: Stock options from Nalu and Saluda Medical obtained prior to 2019, and not exercisable through the duration as my term as INS President, and Editor-in-Chef of the journal, Neuromodulation Technology at the Neural Interface.
- Gladstone C. McDowell II, MD and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Flowonix, TerSera Therapeutics; Grant/Research Support: Medtronic, Flowonix, TerSera Therapeutics; Speaker’s Bureau: TerSera Therapeutics.
- Jason E. Pope, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Ethos, Flowonix, Saluda Medical, PainTEQ, Aurora Spine, Thermaquil, Abbott, Medtronic, Vertos Medical, SPARK, SPR Therapeutics, WISE, TerSera Therapeutics; Grant/Research Support: Ethos Labs, Flowonix, Saluda, PainTEQ, Aurora Spine, Thermaquil, Celeri Health, Abbott, Medtronic, AIS, Boston Scientific, Vertos Medical, Spark; Shareholder: PainTEQ, Aurora Spine, Thermaquil, Celeri Health, SpineThera, AGR, NIS, Vertos Medical, Spark.
- Mark S. Wallace, MD has no financial relationships to disclose.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Mantra Meetings, or the International Neuromodulation Society. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!